PRU vs SCNI · rev $31.19B vs P/E 0.2, rev $1.3M
PRU (PRU) versus Scinai Immunotherapeutics Ltd (SCNI) — a side-by-side from cached financials, not a winner call.
PRU (PRU) common stock.
Scinai Immunotherapeutics Ltd (SCNI) is a biotechnology company listed on NASDAQ.
Latest reported PRU revenue for 2026-06-30 was $31.19B. Net income was $1.58B. PRU currently screens at market cap $0.
Latest reported SCNI revenue for 2025-12-31 was $1.3M. Net income was -$8.3M. Revenue was up 99.2% from 2024-12-31 to 2025-12-31. SCNI currently screens at market cap $1.8M and trailing P/E 0.2.
PRU currently screens at market cap $0. SCNI currently screens at market cap $1.8M and trailing P/E 0.2.
Not investment advice. Open the PRU and SCNI stock pages for the full models.
Not investment advice.